Phase Genomics Accelerates Microbiome Discovery and Antibiotic Resistance tracking with New ProxiMeta™ 8-Pack Including Bundled Analysis
20 juin 2019 09h05 HE
|
Phase Genomics
SEATTLE, Washington, June 20, 2019 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the biotech leader providing proximity ligation solutions for genome and metagenome assembly, announces its new...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
12 juin 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Oxford, UK,...
Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019
10 juin 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
DNV GL Healthcare Focuses on Overcoming Antimicrobial Resistance in Nation's Hospitals
29 mai 2019 16h27 HE
|
DNV GL Business Assurance USA, Inc.
MILFORD, OHIO, May 29, 2019 (GLOBE NEWSWIRE) -- As the Centers for Disease Control and Prevention (CDC) ramps up the nation’s attempts to neutralize antibiotic/anti-microbial resistance (AMR) in...
Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 16h00 HE
|
Melinta Therapeutics
~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~...
Entasis Therapeutics Strengthens Leadership Team with Appointment of Eric Kimble as Chief Commercial Officer
23 avr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
08 avr. 2019 07h30 HE
|
Melinta Therapeutics
MORRISTOWN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
04 avr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious...
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
18 mars 2019 11h00 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN)...
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
14 mars 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...